Welcome to our dedicated page for Acm Research SEC filings (Ticker: ACMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ACM Research, Inc. (ACMR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ACM is a NASDAQ‑listed supplier of wafer and panel processing solutions for semiconductor and advanced packaging applications, and its filings offer detailed insight into its operations, financial performance and corporate structure.
Among the key documents, investors can review Form 10‑K annual reports and Form 10‑Q quarterly reports, which describe ACM’s semiconductor process equipment business spanning cleaning, electroplating, stress‑free polishing, vertical furnace processes, track systems, PECVD, and wafer‑ and panel‑level packaging tools. These reports typically discuss revenue drivers, contributions from its principal operating subsidiary ACM Research (Shanghai), Inc., and risk factors relevant to its markets and listings.
Frequent Form 8‑K current reports from ACM detail material events such as quarterly financial results, preliminary revenue and shipment ranges, backlog disclosures from ACM Shanghai, and capital raising activities at ACM Shanghai under STAR Market regulations. These filings often incorporate the full text of related press releases, providing official context for operating and financing updates.
Users can also locate Form 4 insider transaction reports, which disclose purchases and sales of ACMR equity by directors, officers and other insiders, as well as proxy materials that address governance matters and executive compensation. Stock Titan’s interface surfaces these filings with AI‑powered summaries that explain the significance of long and technical documents, highlight key changes across reporting periods, and make it easier to interpret complex sections of 10‑K, 10‑Q and 8‑K reports.
With real‑time updates from EDGAR and AI‑generated highlights, this page helps investors and analysts quickly understand what ACM Research reports to regulators about its semiconductor equipment and advanced packaging business.
ACM Research (ACMR) filed its Q3 2025 10‑Q, reporting stronger results. Revenue was $269,160 for the quarter versus $203,976 a year ago, with diluted EPS of $0.52. For the nine months, revenue reached $656,879 and diluted EPS was $1.26. Net income attributable to ACM Research, Inc. was $35,889 in Q3.
Gross profit was $113,149 on cost of revenue of $156,011. Operating expenses rose to $84,226, led by higher R&D and SG&A. Cash and cash equivalents were $1,058,909 as of September 30, 2025. Operating cash flow for the nine months was $(44,244), while financing activities provided $738,115, including $622,964 of net proceeds from an issuance of shares by ACM Shanghai.
In September 2025, ACM Shanghai issued 38.6 million ordinary shares in a private offering, lowering ACM Research’s interest in ACM Shanghai from 81.1% to 74.6% at September 30, 2025. Shares outstanding were 59,854,640 Class A and 5,021,811 Class B as of November 3, 2025.
ACM Research, Inc. furnished an 8-K announcing it issued a press release with financial results for the third quarter of 2025. The press release, dated November 5, 2025, is included as Exhibit 99.1 and incorporated by reference.
The disclosure was made under Item 2.02 (Results of Operations and Financial Condition) and is designated as furnished, not filed under the Exchange Act. The filing also lists the company’s Class A common stock trading on Nasdaq under the symbol ACMR.
ACM Research (ACMR) Form 4: CEO, President and Director David H. Wang reported vesting and acquisition of 545,400 stock options at an exercise price of $7.36 on October 27, 2025, from a 2020 performance grant. These options are now exercisable and expire on March 19, 2030.
The vesting occurred after the company’s market capitalization reached $2,553,383,586 under the grant’s formula; remaining tranches vest if market cap reaches $3,553,383,586. Indirect beneficial holdings disclosed include 620,001 shares (Wang‑Chen Family Living Trust), 180,000 (Family Irrevocable Trust for Wang Children), 100,002 (spouse), and 45,837 (daughter).
ACM Research, Inc. filed an 8-K to furnish a press release announcing its preliminary unaudited revenue and shipment information for the third quarter of 2025. The press release, titled “ACM Research Announces Preliminary Unaudited Revenue and Shipments for the Third Quarter 2025,” is included as Exhibit 99.1 and incorporated by reference. The company notes that this information is being furnished under Item 2.02, meaning it is not deemed filed for liability purposes under Section 18 of the Exchange Act or automatically incorporated into other securities filings.
BlackRock, Inc. reported beneficial ownership of 7,420,308 shares of ACM Research, Inc. Class A stock, representing 12.6% of the class. The report, filed as a Schedule 13G/A and signed on 10/02/2025, discloses sole voting power over 7,296,615 shares and sole dispositive power over 7,420,308 shares as of the 09/30/2025 event date. The filing notes that iShares Core S&P Small-Cap ETF holds more than 5% of ACMR common stock. The Schedule 13G states the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
David H. Wang, CEO and Director of ACM Research, Inc. (ACMR), exercised 130,000 vested stock options by net exercise on 09/08/2025 at an exercise price of $1 per share. The filing shows the option was fully vested and the net exercise closed on that date, resulting in 610,002 shares held directly after the transaction. The report also discloses indirect holdings: 100,002 shares held by Jing Chen (his wife), 45,837 by his daughter Sophia Wang, 180,000 by a family trust for his children, and 620,001 by the Wang-Chen Family Living Trust. The Form 4 was signed by an attorney-in-fact on 09/30/2025.
ACM Research, Inc. filed a current report to let investors know it issued a press release on September 29, 2025. The release, titled “Research’s Operating Subsidiary Research (Shanghai) Provides Backlog Data,” comes from its Shanghai operating subsidiary and is attached to the report as an exhibit.
Research, Inc. filed a current report to inform investors about a press release issued on September 24, 2025. The press release, titled “Research’s Operating Subsidiary Research (Shanghai) Announces Issuance Report on Private Offering of Ordinary Shares,” describes activity at the company’s Shanghai operating subsidiary related to a private offering of ordinary shares.
The full text of this press release is included as Exhibit 99.1 and incorporated by reference, and the filing also includes a cover page interactive data file as Exhibit 104.
Tracy Liu, a director of ACM Research, Inc. (ACMR), exercised 15,000 fully vested stock options on September 17, 2025, at a $1 exercise price, creating 15,000 shares of Class A common stock. The same day, the reporting person sold 15,000 shares at $33.00 per share pursuant to a Rule 10b5-1 trading plan adopted March 6, 2025. After these transactions, Ms. Liu beneficially owned 110,772 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on behalf of Ms. Liu on September 19, 2025.
The reporting person, Jian Wang, exercised a fully vested stock option to acquire 30,000 shares of ACM Research Class A common stock at an exercise price of $5.60 per share and concurrently sold 30,000 shares under a Rule 10b5-1 trading plan at $35.00 per share. Following these transactions, the report shows beneficial ownership of 253,158 shares, down from 283,158 shares before the transactions.
The filing states the option was previously issued and fully exercisable and that the sales were effected pursuant to a 10b5-1 plan adopted on May 20, 2025. The form identifies the reporting person as an officer and notes an officer/subsidiary leadership role in ACM Research (Shanghai), Inc.